Ethmoid tumor and oncogenic osteomalacia: Case report and review of the literature

Villepelet, Aude; Casiraghi, Odile; Temam, Stéphane; Moya‐Plana, Antoine

doi:10.1016/j.anorl.2018.07.001

Cited by 8 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 70 cases in the head/neck have been reported in addition to the cases reported from our institute, and only 10 cases among them were refractory. (4,11,12,(14)(15)(16) Although this rate is higher than ours, it is plausible that TIO tumors in the head/neck have a favorable outcome. It does not make sense to compare the delicate differences between our cases and those reported in various institutes because other cases are so scattered.…”

Section: Discussioncontrasting

confidence: 63%

“…Among each tumor location, head/neck tumors exerted the highest recovery rate, whereas spine tumors were most likely to be refractory. More than 70 cases in the head/neck have been reported in addition to the cases reported from our institute, and only 10 cases among them were refractory . Although this rate is higher than ours, it is plausible that TIO tumors in the head/neck have a favorable outcome.…”

Section: Discussioncontrasting

confidence: 53%

“…The overall recovery rate was 88.4% in our cohort. Previously reported recovery rates in other studies have varied from 72.7% to 100% . Small sample sizes, gaps in medical resources, focuses on different tumor locations, and different follow‐up periods of these studies all led to discrepancies.…”

Section: Discussionmentioning

confidence: 95%

“…Previously reported recovery rates in other studies have varied from 72.7% to 100%. (4,5,(9)(10)(11)(12) Small sample sizes, gaps in medical resources, focuses on different tumor locations, and different follow-up periods of these studies all led to discrepancies. The result of our cohort may provide convincing evidence for this predicament.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study

Jiang

Huo

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study

Jiang

Huo

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…4,5 Otolaryngologists and maxillofacial surgeons might not be familiar with PMTs because they are uncommon in the head and neck and rarely involve the naso-ethmoidal region. 6,7 At this level, PMTs often lack the distinctive (grungy) calcified matrix and multinucleated giant cells that characterize PMTs of soft tissues and bones and commonly present clusters of mature adipocytes and florid hemangiopericytoma-like vasculature associated with fascicles of myoid-appearing cells that may mimic other vascular and perivascular tumor. 5,8 To this regard, even though not specific, the immunoreactivity of the neoplastic cells for CD56 may be helpful because its expression in mesenchymal tumors is limited.…”

mentioning

confidence: 99%